Fig. 1: Clinical efficacy of FMT in combination with ICI in patients with previously untreated NSCLC and melanoma. | Nature Medicine

Fig. 1: Clinical efficacy of FMT in combination with ICI in patients with previously untreated NSCLC and melanoma.

From: Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial

Fig. 1: Clinical efficacy of FMT in combination with ICI in patients with previously untreated NSCLC and melanoma.

a, Patient enrollment diagram. b–c, Waterfall plot showing the best objective response, with PD-L1 tumor expression shown for each patient on the horizontal axis (b) and swimmer plot showing the time-on-treatment after FMT in combination with pembrolizumab in n = 20 patients with NSCLC (c). d–e, Waterfall plot showing the best objective response (d) and swimmer plot showing the time-on-treatment after FMT in combination with ipilimumab plus nivolumab in n = 20 patients with melanoma (e). CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease. Asterisks in the swimmer plot indicate that ICI treatment was discontinued at the moment of last-follow-up. Dashed lines in the waterfall plot at −30% indicate at least PR, and dashed lines in the waterfall plot at +20% indicate PD. Asterisks in the waterfall plot indicate disease progression due to clinical progression or death. PD-L1, programmed death ligand 1.

Back to article page